By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Business of developing therapeutics3.45M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States (US)128.94M100.00%